| Trials . | DAPA-MI . | DECLARE-TIMI 58 . | DAPA-HF . |
|---|---|---|---|
| Target population | AMI | ASCVD + DM | HF |
| Subgroup | Placebo | Previous MI | Ischaemic origin |
| Number of patents in the subgroup | 1998 | 3584 | 2674 |
| Demographics | |||
| Age (year) | 63 | 62 | 68 |
| Male sex (%) | 79 | 76.4 | 79.9 |
| Europe (%) | 100 | 49.8 | 52.5 |
| Weight (kg) | 85.5 | 91 | NA |
| eGFR (mL/min/1.73 m2) | 83.4 | 88 | 63.7 |
| HbA1c (%) | 5.7 | 8 | NA |
| Medical history | |||
| Myocardial infarction (%) | 9.5 | 100 | 72.5 |
| Stroke (%) | 2.5 | 6.1 | 10.7 |
| Diabetes (%) | NA | 100 | 49.9 |
| Heart failure (%) | NA | 21.5 | 46.1 |
| Baseline medication | |||
| ACE inhibitor/ARB use (%) | 91.8 | 84.1 | 84.6 |
| Beta-blockers use (%) | 89.9 | 82.2 | 96 |
| Statins use (%) | 94.9 | 91.1 | 83.5 |
| Outcomesa | |||
| Follow-up duration (year) | 1 | 4.2 | 1.5 |
| CV death/hospitalization for HF (%) | 2.6 | 10.5 | 20.9 |
| MACE (%) | 3.6 | 17.8 | NA |
| CV death (%) | 1.2 | 5.3 | 12.5 |
| All cause death (%) | 1.7 | 10.3 | 15.2 |
| Hospitalization for HF | 1.6 | 6.3 | 12.7 |
| Trials . | DAPA-MI . | DECLARE-TIMI 58 . | DAPA-HF . |
|---|---|---|---|
| Target population | AMI | ASCVD + DM | HF |
| Subgroup | Placebo | Previous MI | Ischaemic origin |
| Number of patents in the subgroup | 1998 | 3584 | 2674 |
| Demographics | |||
| Age (year) | 63 | 62 | 68 |
| Male sex (%) | 79 | 76.4 | 79.9 |
| Europe (%) | 100 | 49.8 | 52.5 |
| Weight (kg) | 85.5 | 91 | NA |
| eGFR (mL/min/1.73 m2) | 83.4 | 88 | 63.7 |
| HbA1c (%) | 5.7 | 8 | NA |
| Medical history | |||
| Myocardial infarction (%) | 9.5 | 100 | 72.5 |
| Stroke (%) | 2.5 | 6.1 | 10.7 |
| Diabetes (%) | NA | 100 | 49.9 |
| Heart failure (%) | NA | 21.5 | 46.1 |
| Baseline medication | |||
| ACE inhibitor/ARB use (%) | 91.8 | 84.1 | 84.6 |
| Beta-blockers use (%) | 89.9 | 82.2 | 96 |
| Statins use (%) | 94.9 | 91.1 | 83.5 |
| Outcomesa | |||
| Follow-up duration (year) | 1 | 4.2 | 1.5 |
| CV death/hospitalization for HF (%) | 2.6 | 10.5 | 20.9 |
| MACE (%) | 3.6 | 17.8 | NA |
| CV death (%) | 1.2 | 5.3 | 12.5 |
| All cause death (%) | 1.7 | 10.3 | 15.2 |
| Hospitalization for HF | 1.6 | 6.3 | 12.7 |
aTo ensure maximum comparability with the DAPA-MI placebo group, the event rates reported above in the DECLARE-TIMI 58 and DAPA-HF are derived from the placebo groups of each respective subgroup.
| Trials . | DAPA-MI . | DECLARE-TIMI 58 . | DAPA-HF . |
|---|---|---|---|
| Target population | AMI | ASCVD + DM | HF |
| Subgroup | Placebo | Previous MI | Ischaemic origin |
| Number of patents in the subgroup | 1998 | 3584 | 2674 |
| Demographics | |||
| Age (year) | 63 | 62 | 68 |
| Male sex (%) | 79 | 76.4 | 79.9 |
| Europe (%) | 100 | 49.8 | 52.5 |
| Weight (kg) | 85.5 | 91 | NA |
| eGFR (mL/min/1.73 m2) | 83.4 | 88 | 63.7 |
| HbA1c (%) | 5.7 | 8 | NA |
| Medical history | |||
| Myocardial infarction (%) | 9.5 | 100 | 72.5 |
| Stroke (%) | 2.5 | 6.1 | 10.7 |
| Diabetes (%) | NA | 100 | 49.9 |
| Heart failure (%) | NA | 21.5 | 46.1 |
| Baseline medication | |||
| ACE inhibitor/ARB use (%) | 91.8 | 84.1 | 84.6 |
| Beta-blockers use (%) | 89.9 | 82.2 | 96 |
| Statins use (%) | 94.9 | 91.1 | 83.5 |
| Outcomesa | |||
| Follow-up duration (year) | 1 | 4.2 | 1.5 |
| CV death/hospitalization for HF (%) | 2.6 | 10.5 | 20.9 |
| MACE (%) | 3.6 | 17.8 | NA |
| CV death (%) | 1.2 | 5.3 | 12.5 |
| All cause death (%) | 1.7 | 10.3 | 15.2 |
| Hospitalization for HF | 1.6 | 6.3 | 12.7 |
| Trials . | DAPA-MI . | DECLARE-TIMI 58 . | DAPA-HF . |
|---|---|---|---|
| Target population | AMI | ASCVD + DM | HF |
| Subgroup | Placebo | Previous MI | Ischaemic origin |
| Number of patents in the subgroup | 1998 | 3584 | 2674 |
| Demographics | |||
| Age (year) | 63 | 62 | 68 |
| Male sex (%) | 79 | 76.4 | 79.9 |
| Europe (%) | 100 | 49.8 | 52.5 |
| Weight (kg) | 85.5 | 91 | NA |
| eGFR (mL/min/1.73 m2) | 83.4 | 88 | 63.7 |
| HbA1c (%) | 5.7 | 8 | NA |
| Medical history | |||
| Myocardial infarction (%) | 9.5 | 100 | 72.5 |
| Stroke (%) | 2.5 | 6.1 | 10.7 |
| Diabetes (%) | NA | 100 | 49.9 |
| Heart failure (%) | NA | 21.5 | 46.1 |
| Baseline medication | |||
| ACE inhibitor/ARB use (%) | 91.8 | 84.1 | 84.6 |
| Beta-blockers use (%) | 89.9 | 82.2 | 96 |
| Statins use (%) | 94.9 | 91.1 | 83.5 |
| Outcomesa | |||
| Follow-up duration (year) | 1 | 4.2 | 1.5 |
| CV death/hospitalization for HF (%) | 2.6 | 10.5 | 20.9 |
| MACE (%) | 3.6 | 17.8 | NA |
| CV death (%) | 1.2 | 5.3 | 12.5 |
| All cause death (%) | 1.7 | 10.3 | 15.2 |
| Hospitalization for HF | 1.6 | 6.3 | 12.7 |
aTo ensure maximum comparability with the DAPA-MI placebo group, the event rates reported above in the DECLARE-TIMI 58 and DAPA-HF are derived from the placebo groups of each respective subgroup.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
